When other drugs became detectable, riders began achieving the effects of transfusion more effectively by using
erythropoietin, known as EPO, a drug to increase red-cell production in anaemia sufferers. EPO became widespread, as a flurry of exposures and confessions revealed in 2006 and 2007. "When I saw riders with fat arses climbing cols like aeroplanes, I understood what was happening", said the Colombian rider,
Luis Herrera. EPO's problem for testers was that like testosterone and, before that, cortisone, they could not distinguish it from what the body produced naturally. For the first time, said Jean-Pierre de Mondenard, authorities had to settle not for the presence of a drug but its presence in unusual quantities. Testers set a haematocrit limit of 50 per cent and "rested" riders who exceeded it.
Bjarne Riis, the Danish rider who won the Tour in 1996, was known as "Mr 60 per cent" among riders. On 25 May 2007, he admitted he had used EPO from 1993 to 1998, including 1996 when he won the Tour. Cynicism set in among both riders and officials.
Jacques Goddet, organiser of the Tour from 1936 to 1987, said in 1999: :I brought controls to the Tour in the wake of Tom Simpson's death in 1967 – and the riders went on strike. After the discoveries made [into the so-called 1998 Festina scandal, see below], I feel real resentment towards the medical and scientific powers who deceived us for 30 years. The controls are almost always negative, which means that the labs have been making serious mistakes, mistakes that have only served to speed up the growth of this evil. The controls we developed after Simpson's death were a lie, covered up by the highest scientific and medical authorities, and I condemn them. Since 1997, the
Swiss Laboratory for Doping Analyses is the testing laboratory of the
Tour de France.
1998 Festina scandal On 8 July 1998, French
Customs arrested
Willy Voet, a soigneur for the
Festina team, for the possession of illegal drugs, including
narcotics,
erythropoietin (EPO),
growth hormones,
testosterone, and amphetamines. Voet later described many common doping practices in his book,
Massacre à la Chaîne. On 23 July 1998, French police raided several teams' hotels and found drugs in the possession of the
TVM team. As news spread, riders staged a sit-down strike during the 17th stage. After mediation by
Jean-Marie Leblanc, the director of the Tour, police agreed to limit the most heavy-handed tactics and riders agreed to continue. Many riders and teams had already abandoned the race and only 111 riders completed the stage. In a 2000 trial, it became clear that the management and health officials of Festina had organized drug-taking within the team.
Richard Virenque, a top Festina rider, finally confessed after being ridiculed for maintaining that if he was doping he was somehow not consciously aware of it – as the satirical television programme, ''
Les Guignols de l'Info'', put it: "à l'insu de mon plein gré" ("of my own free will but without my knowing"). In the years following the 1998
Festina affair, anti-doping measures were put into effect by race organizers and the UCI, including more frequent testing and new tests for
blood doping transfusions and EPO use. The
World Anti-Doping Agency (WADA) was also created to help governments in anti-doping. Evidence of drugs persisted and in 2004 came new allegations. In January,
Philippe Gaumont, a rider with the
Cofidis team, told investigators and the press that
steroids,
human growth hormone, EPO, and amphetamines were endemic to the team. In June, British cyclist
David Millar, also of Cofidis, and
time trial world champion, was detained by French police, his apartment searched and two used EPO syringes found.
Jesús Manzano, a Spanish rider then recently dismissed by the Kelme team, told the Madrid sports newspaper
AS he had been forced by his former team to take banned substances and that they had taught him to evade detection. The Kelme team itself was ultimately a casualty of the disclosures, which Manzano judged to be "an eye for an eye and a tooth for a tooth."
Lance Armstrong Lance Armstrong has become a symbol for doping at the Tour de France. Suspicions arose initially over his association with Italian physician
Michele Ferrari and his extraordinary achievements on the road. In 1999, Armstrong failed tests for a
glucocorticosteroid hormone. Armstrong explained he had used an external
cortisone ointment to treat a saddle sore and produced a prescription for it. The amount detected was below the threshold and said to be consistent with the amount used for a topical skin cream, but UCI rules required that prescriptions be shown to sports authorities in advance of use. Armstrong's former assistant, Mike Anderson, stated that Armstrong used a substance with a trade name similar to "androstenine". This resulted in a lawsuit against Anderson and a countersuit against Armstrong. In late August 2005, one month after Lance Armstrong's seventh consecutive Tour victory, the French sports newspaper ''
L'Équipe claimed evidence that Armstrong had used EPO in the 1999 Tour de France. The claim was based on urine samples archived by the French National Laboratory for Doping Detection (LNDD) for research. Armstrong denied using EPO and the UCI did not penalise him because of the lack of a duplicate sample. The UCI confirmed that its own doctor Mario Zorzoli leaked the 15 forms tying Armstrong to the failed tests to L'Équipe''. On 22 October 2012, Armstrong was banned for life and stripped of all his titles since 1 August 1998, including all seven of his Tour de France victories, because an investigation by
USADA concluded that he had been engaged in a massive doping scheme. Due to 20 of the 21 podium finishers "directly tied to likely doping through admissions, sanctions, public investigations or exceeding the UCI hematocrit (a blood test to discover EPO use) threshold", Escartin's third-place finish in the 1999 Tour de France stands as the lone of the 21 podium finishes that was untainted, during the years (1999–2005) in which Lance Armstrong finished the Tour de France in first place.
2006 Tour de France Operación Puerto investigation prologue In 2006, several riders, including
Jan Ullrich and
Ivan Basso, were barred from the
eve of the race amid allegations by Spanish police as a result of their
Operación Puerto investigation. The
Astana-Würth team could not start because, despite a ruling by the
Court of Arbitration for Sport, five of its nine Tour riders were barred after being officially named in the Operacion Puerto affair. With only four riders remaining (
Alexander Vinokourov,
Andrey Kashechkin,
Carlos Barredo and
Luis León Sánchez) the team did not have the minimum number of riders demanded by the rules to enter. The cyclists excluded from
2006 Tour de France were: •
Astana-Würth team: •
Alberto Contador, cleared by Spanish court on 26 July 2006. •
Allan Davis, cleared by Spanish court on 26 July 2006. Landis' personal doctor later revealed the test had found a ratio of 11:1 in Landis' blood; the permitted ratio is 4:1. after
T-Mobile's German rider,
Patrik Sinkewitz, failed a test for testosterone on 8 June at a pre-Tour training camp.
Alessandro Petacchi, a
sprint specialist, failed a test for
salbutamol at
Pinerolo on 23 May in the
2007 Giro d'Italia, the day of the third of his five-stage wins in the event. Petacchi, an
asthma sufferer, was suspended by
Milram and forced to miss the Tour de France. He was later cleared after the drug was deemed to be therapeutic use. On 19 June it was revealed that the leader,
Michael Rasmussen, was under suspicion for missing two out-of-competition doping tests. The Dane had been dropped by the
Danish Cycling Union and his Olympic place was under review. However, with information available at the time, Rasmussen had not committed an offence under UCI rules and he remained in the yellow jersey. On 8 November Rasmussen admitted providing false information to the UCI. Then on 24 July it was revealed that
Alexander Vinokourov had failed a test for
blood doping after the time trial in
Albi, which he won by more than a minute As a result, the
Astana Team withdrew. Vinokourov's teammates
Andreas Klöden and
Andrey Kashechkin were fifth and seventh at the time. Vinokourov also failed tests for blood doping after winning Monday's stage 15. Following the Vinokourov announcement, Tour director
Christian Prudhomme said professional cycling needed a "complete overhaul" to combat doping. A day later, after winning the 16th stage on the
Col d'Aubisque—a victory that assured he would be the overall winner—it was alleged that Rasmussen had lied to his
Rabobank team about his whereabouts on 13 and 14 June, prior to the Tour. For breaching team rules, he was removed from the race. It was later revealed that the Tour organiser,
Amaury Sport Organisation, had pressed Rabobank to remove Rasmussen. On the same day,
Team Cofidis pulled out following the failed test on their rider
Cristian Moreni. The Tour continued to be embroiled in doping controversies even after it finished. It emerged that Spanish cyclist (and 16th placed rider)
Iban Mayo had failed a test for
EPO on the second rest day, on 24 July. He was suspended by his team
Saunier Duval–Prodir. Mayo had previously failed tests for synthetic
testosterone during the
2007 Giro d'Italia, but the UCI found that he had not breached any doping regulation. Tour winner
Alberto Contador also continued to be linked to doping allegations, focussing on his relationship with Eufemiano Fuentes and his role in Operación Puerto, but without new revelations. Contador was tested in the Tour after stages 14, 17, and 18 and no discrepancies were reported. Several participants, such as
Sébastien Hinault, implied that he is no better than Rasmussen. On 30 July German doping expert
Werner Franke accused him of having taken drugs in the past. == 2012 USADA report ==